Monitoring of insulin pump therapy in children, adolescents, and young adults with type 1 diabetes mellitus in the Russian Federation

Cover Page
Open Access Open Access
Restricted Access Subscription Access


Background. Insulin pump therapy in increasingly frequently used in the Russian Federation in recent years, which requires an evaluation of the treatment in order to improve its efficacy and safety.

Objective — the study was aimed at complex monitoring (long-term efficacy and safety, state of medical care, factors associated with metabolic control, and factors hindering its use) of the continuous subcutaneous insulin infusion (CSII) in children, adolescents, and young adults with type 1 diabetes mellitus (DM1) from various regions of the Russian Federation.

Material and methods. Data of 395 DM1 children and adolescents from 60 regions of the Russian Federation were collected from the pediatric CSII register of the Endocrinology Research Center. The following data were analyzed in different age groups (0 to 7 years, 8 to 11 years, 12 to 17 years, and 18 to 25 years): glycemic control, the incidence of acute complications, discontinuation of CSII, characteristic features of blood glucose monitoring, and supplies coverage.

Results. Initiation of CSII is accompanied by decrease in HbA1c level with the lowest values within the period from 6 to 24 months (–0.7±1.5% compared to the baseline level). However, 6 years after CSII initiation, HbA1c values do not differ significantly from the baseline values. The target HbA1c level (less than 7.5%) is observed in 43.6% of children aged 0 to 7 years, 32.7% of children aged 8 to 11 years, 24.2% of adolescents aged 12 to 17 years, and 28% of young adults aged 18 to 25 years. Regular self-monitoring of glycemia, 4 and more times per day, was performed by 83% of patients, while the frequency of continuous glucose monitoring (CGM) was low, 12.7% in the whole population. The incidence of acute complications in children and adolescents under 18 years did not differ significantly and the lowest incidence was observed in the age group 18 to 25 years. The effectiveness of CSII depended on the frequency of self-monitoring, CGM use, and supplies coverage. CSII discontinuation rate was 4.6 cases per 100 patient-years. The main reasons for discontinuation of CSII included the inconvenience of its use and the cost of supplies.

Conclusions. Many children and the majority of adolescents with DM1, who use CSII, did not reach target HbA1c level despite the adequate self-monitoring. Many patients do not use CGM and refuse CSII. This necessitates the efforts to improve the efficacy and overcome barriers to the use of CGM and CSII.

Dmitry N. Laptev

Author for correspondence.
ORCID iD: 0000-0002-4316-8546
SPIN-code: 2419-4019
Endocrinology Research Centre
Russian Federation, 117036, Russia, Moscow, D.Ulyanova 11

11, Dm. Ulyanova street, Moscow, 117036

Svetlana V. Pereverzeva
ORCID iD: 0000-0002-5104-7218
SPIN-code: 3972-2831
Endocrinology Research Centre
Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

Physician, Department of Pediatrics

Andrey O. Emelyanov
ORCID iD: 0000-0002-3742-0231
SPIN-code: 8110-5540
Endocrinology Research Centre
Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

PhD, senior scientist, Department of Pediatrics

Valentina A. Peterkova
ORCID iD: 0000-0002-5507-4627
SPIN-code: 4009-2463
Endocrinology Research Centre
Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

Academician of RAS, professor, PhD, Head of Pediatric Department

  • Дедов И.И., Петеркова В.А., Кураева Т.Л., и др. Инсулиновая помпа (помощь врачу и пациенту для эффективного управления сахарным диабетом). — Москва. 2014. [Dedov II, Peterkova VA, Kuraeva TL, Laptev DN. Insulinovaya pompa (Pomoshch’ Vrachu I Patsientu Dlya Effektivnogo Upravleniya Diabetom). Moscow. 2014. (In Russ.)].
  • Лаптев Д.Н. Преимущество помповой инсулинотерапии и систем мониторирования гликемии в реальном времени в отношении снижения частоты эпизодов гипогликемии у детей и подростков с сахарным диабетом 1-го типа. // Проблемы эндокринологии. — 2014. — Т. 60. — № 2. — С. 24-30. [Laptev DN. The advantages of insulin pump therapy and real time glucose monitoring systems as the tools for reducing the frequency of hypoglycemic episodes in the children and adolescents with type 1 diabetes mellitus. Problems of Endocrinology. 2014;60(2):24-30. (In Russ.)]. doi: 10.14341/probl201460224-30.
  • Шестакова М.В., Майоров А.Ю., Филиппов Ю.И., и др. Федеральные клинические рекомендации по помповой инсулинотерапии и непрерывному мониторированию гликемии у больных сахарным диабетом. Проект. // Проблемы эндокринологии. — 2015. — Т. 61. — № 6. — С. 55-78. [Shestakova MV, Mayorov AY, Philippov YI, et al. Russian national guidelines on insulin pump therapy and continuous glucose monitoring for diabetes mellitus patients. DRAFT. Problems of Endocrinology. 2015;61(6):55-78. (In Russ.)]. doi: 10.14341/probl201561655-78.
  • Лаптев Д.Н., Филиппов Ю.И., Емельянов А.О. и др. Оптимизация настроек инсулиновых помп у детей и подростков с сахарным диабетом 1-го типа с учетом возрастных особенностей. // Сахарный диабет. — 2013. — Т. 16. — № 3. — С. 109-115. [Laptev DN, Philippov YI, Emel’yanov AO, Kuraeva TL. Age-adjustment of insulin pump settings in children and adolescents with type 1 diabetes mellitus. Diabetes Mellitus. 2013;16(3):109-115. (In Russ.)]. doi: 10.14341/2072-0351-98.
  • Петеркова В.А., Кураева Т.Л., Емельянов А.О., и др. Помповая инсулинотерапия сахарного диабета у детей и подростков (методическое пособие для педиатров-эндокринологов). — Москва. 2011. [Peterkova VA, Kuraeva TL, Emel’yanov AO, et al. Pompovaya Insulinoterapiya Sakharnogo Diabeta u Detei i Podrostkov (Metodicheskoe Posobie Dlya Pediatrov-Endokrinologov). Moscow. 2011. (In Russ.)].
  • Емельянов А.О., Кураева Т.Л., Лаптев Д.Н., и др. Проспективное наблюдение эффективности и безопасности помповой инсулинотерапии у детей и подростков. // Сахарный диабет. — 2010. — Т. 13. — № 3. — С. 143-146. [Emel’yanov AO, Kuraeva TL, Laptev DN, Peterkova VA. Prospective study of efficacy and safety of insulin pump therapy in children and adolescents. Diabetes mellitus. 2010;13(3):143-146. (In Russ.)]. doi: 10.14341/2072-0351-5503.
  • Петеркова В.А., Кураева Т.Л., Емельянов А.О., и др. Помповая инсулинотерапия сахарного диабета у детей и подростков. Российский консенсус детских эндокринологов. // Проблемы эндокринологии. — 2012. — Т. 58. — № 2. — С. 2-18. [Dedov II, Peterkova VA, Kuraeva TL, et al. Pompovaya insulinoterapiya sakharnogo diabeta u detei i podrostkov. Rossiiskii konsensus detskikh endokrinologov. Problems of Endocrinology. 2012;58(2):3-18. (In Russ.)].
  • Phillip M, Battelino T, Rodriguez H, et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007;30(6):1653-1662. doi: 10.2337/dc07-9922.
  • Peterkova V, Andrianova E, Malievsky O, et al. Diabetes management and glycaemic control in Russian children, adolescents and young adults with type 1 diabetes (T1D) in the TEENS study. Proceedings of the IDF World Diabetes Congress in Melbourne; 2013 December 2–6. Poster PD-0792.
  • Sherr JL, Hermann JM, Campbell F, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59(1):87-91. doi: 10.1007/s00125-015-3790-6.
  • Tanenbaum ML, Hanes SJ, Miller KM, et al. Diabetes Device Use in Adults With Type 1 Diabetes: Barriers to Uptake and Potential Intervention Targets. Diabetes Care. 2017;40(2):181-187. doi: 10.2337/dc16-1536.
  • Витебская А.В., Попович А.В. Причины отказов от помповой инсулинотерапии детей и подростков с сахарным диабетом 1-го типа. // Поликлиника. — 2016. — №1-2. — C. 35-39. [Vitebskaya AV, Popovich AV. Causes of insulin pump therapy refusal in children and adolescents with diabetes mellitus type 1. Poliklinika. 2016;(1-2):35-39. (In Russ.)].
  • Laptev DN, Pereverzeva SV, Emelyanov AO, et al. Improvement of glycemic control with remote support in children adolescents with type 1 diabetes mellitus on insulin-pump therapy. In: Abstracts from ATTD 2017 10th International Conference on Advanced Technologies & Treatments for Diabetes Paris, France-February 15-18, 2017. Diabetes Technol Ther. 2017;19(S1):A1-A133. doi: 10.1089/dia.2017.2525.abstracts.

Supplementary files

Supplementary Files Action
1. Fig. 1. Dynamics of HbA1c level after switching to pump insulin therapy. View (110KB) Indexing metadata
2. Fig. 2. The level of HbA1c, depending on the frequency of self-monitoring performed per day (p <0.05 between groups). View (82KB) Indexing metadata
3. Fig. 3. The value of HbA1c and the frequency of HbA1c are less than 7.5%, depending on the use of LMWH (p <0.05) between the groups for both indicators. View (102KB) Indexing metadata
4. Fig. 4. Structure and frequency of refusals from using an insulin pump. View (61KB) Indexing metadata


Abstract - 291

PDF (Russian) - 27

Remote (Russian) - 109


Copyright (c) 2018 Laptev D.N., Pereverzeva S.V., Emelyanov A.O., Peterkova V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.